NCT06340958: An ongoing trial by Clexio Biosciences Ltd.
This trial is ongoing. It must report results 6 months, 2 weeks from now.
Full data
| Full entry on ClinicalTrials.gov | NCT06340958 |
|---|---|
| Title | A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Parallel-Design, Phase 2 Study to Assess the Efficacy and Safety of CLE-100 as an Adjunctive Treatment for Major Depressive Disorder Patients With Inadequate Response to Standard Antidepressants |
| Results Status | Ongoing |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | March 18, 2024 |
| Completion date | June 6, 2025 |
| Required reporting date | June 6, 2026, midnight |
| Actual reporting date | None |
| Date last checked at ClinicalTrials.gov | Nov. 17, 2025 |
| Days late | None |